Garuda Therapeutics is a biotech startup that focuses on developing hematopoietic stem cell (HSC) therapies. Hematopoietic stem cells are the cells that give rise to all other blood cells. The company's technology aims to treat a wide range of severe and life-threatening diseases, with the potential to cure more than 70 diseases.

Garuda's business model is based on their platform technology that generates self-renewing blood stem cells. This technology is designed to provide patients with quick and broad access to consistent, durable, and HLA-compatible (Human Leukocyte Antigen - a protein on cells that the immune system uses to identify self and non-self cells) blood stem cell therapies.

What sets Garuda apart is its off-the-shelf offering, the first in the industry. This means that the therapies they develop do not rely on donor or patient cells, which can often be a limiting factor in stem cell therapies. This could potentially eliminate dependency on donors or patient cells, making the treatment more accessible to a larger number of patients.

The company was founded by experts in blood stem cell and bone marrow transplants, as well as leaders with expertise in bringing transformative medicines to patients. The team includes Dhvanit Shah, Ph.D., the Founder, President, and CEO, and other experts from prestigious institutions such as the Harvard Stem Cell Institute and the Broad Institute of MIT and Harvard.

In terms of revenue, Garuda Therapeutics makes money by developing and selling their stem cell therapies. As a biotech company, they may also generate income through partnerships with other healthcare companies, licensing their technology, or receiving grants for their research.

Keywords: Biotech, Hematopoietic Stem Cell Therapies, Off-the-Shelf Therapies, Blood Diseases, Self-Renewing Cells, HLA-Compatible, Donor Independent, Transformative Medicines, Expert Leadership, Revenue Generation.